Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age

Background:Dalbavancin is a novel lipoglycopeptide antibiotic that has potent in vitro activity against Gram-positive microorganisms.Methods:We performed a phase 1, open-label, multicenter study to investigate the pharmacokinetics (PK) and safety of a single dose of intravenous dalbavancin in hospit